Primary extranodal lymphoma of the glands. Literature review and options for best practice in 2019.


Por: Belkacemi Y, Sio TT, Colson-Durand L, Onal C, Villà S, Anacak Y, Krengli M, Thariat J, Ugurluer G, Miller RC, Mirimanoff RO, Ozsahin M and To NH

Publicada: 1 mar 2019 Ahead of Print: 18 ene 2019
Resumen:
Primary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic options. In the literature, many EN-NHL types were reported from limited series which only allowed narrow views for elucidating prognostic factors and defining the role of loco-regional therapies in the era of new systemic and biologically targeted therapies. The Rare Cancer Network (RCN), an international multidisciplinary consortium, has published a number of reports on several EN-NHL sites which included many gland locations. In this review, we will focus on the recent literature for a selected number of EN-NHL types in both exocrine and endocrine gland locations. We aim to provide renewed and clear messages for the best practice in 2019 for diagnosis, histopathology, treatments, and also their prognostic implications. We believe that better understanding of molecular and genetic characteristics of these particular diseases is crucial for an appropriate management in the era of personalized treatment developments.

Filiaciones:
Belkacemi Y:
 APHP, Henri Mondor University Hospital, Department of Radiation Oncology and Henri Mondor Breast Center, University of Paris - Est Créteil (UPEC), INSERM, U955 Eq07, Créteil, France

Sio TT:
 Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona, USA

Colson-Durand L:
 APHP, Henri Mondor University Hospital, Department of Radiation Oncology and Henri Mondor Breast Center, University of Paris - Est Créteil (UPEC), INSERM, U955 Eq07, Créteil, France

Onal C:
 Baskent University, Faculty of Medicine, Department of Radiation Oncology, Adana, Turkey

:
 Catalan Institute of Oncology, Department of Radiation Oncology, HU Germans Trias, Badalona, Catalonia, Spain

Anacak Y:
 Ege University Faculty of Medicine. Department of Radiation Oncology. Izmir, Turkey

Krengli M:
 Division of Radiotherapy, University of Piemonte Orientale, Novara, Italy

Thariat J:
 UNICANCER. Centre Antoine Lacassagne, Nice, France

Ugurluer G:
 Acibadem University, School of Medicine, Acibadem Adana Hospital, Department of Radiation Oncology, Adana, Turkey

Miller RC:
 Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona, USA

Mirimanoff RO:
 University of Lausanne and Centre Hospitalier Universitaire Vaudois (CHUV), Department of Radiation Oncology, Lausanne, Switzerland

Ozsahin M:
 University of Lausanne and Centre Hospitalier Universitaire Vaudois (CHUV), Department of Radiation Oncology, Lausanne, Switzerland

To NH:
 APHP, Henri Mondor University Hospital, Department of Radiation Oncology and Henri Mondor Breast Center, University of Paris - Est Créteil (UPEC), INSERM, U955 Eq07, Créteil, France
ISSN: 10408428





CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Editorial
Elsevier BV, STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA, Países Bajos
Tipo de documento: Article
Volumen: 135 Número:
Páginas: 8-19
WOS Id: 000461262800002
ID de PubMed: 30819450

MÉTRICAS